MX2021003116A - Profarmacos macromoleculares a base de polimero. - Google Patents
Profarmacos macromoleculares a base de polimero.Info
- Publication number
- MX2021003116A MX2021003116A MX2021003116A MX2021003116A MX2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A MX 2021003116 A MX2021003116 A MX 2021003116A
- Authority
- MX
- Mexico
- Prior art keywords
- polymer
- macromolecular prodrugs
- based macromolecular
- prodrugs
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732199P | 2018-09-17 | 2018-09-17 | |
| PCT/US2019/051457 WO2020061007A1 (en) | 2018-09-17 | 2019-09-17 | Polymer-based macromolecular prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003116A true MX2021003116A (es) | 2021-05-14 |
Family
ID=69887739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003116A MX2021003116A (es) | 2018-09-17 | 2019-09-17 | Profarmacos macromoleculares a base de polimero. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11253603B2 (https=) |
| EP (1) | EP3852793B1 (https=) |
| JP (1) | JP7546552B2 (https=) |
| KR (1) | KR20210072002A (https=) |
| CN (2) | CN119950749A (https=) |
| AU (1) | AU2019344783B2 (https=) |
| CA (1) | CA3112778A1 (https=) |
| EA (1) | EA202190799A1 (https=) |
| MX (1) | MX2021003116A (https=) |
| WO (1) | WO2020061007A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7546552B2 (ja) * | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| CN115443947B (zh) * | 2022-10-12 | 2023-11-21 | 江苏省人民医院（南京医科大学第一附属医院） | 高血压动物模型的制备方法 |
| WO2025101904A1 (en) * | 2023-11-08 | 2025-05-15 | The Children's Hospital Of Philadelphia | Norepinephrine transporter-targeted prodrugs for cancer therapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999052861A1 (de) * | 1998-04-09 | 1999-10-21 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik |
| JP2002255821A (ja) * | 2001-03-06 | 2002-09-11 | Yakult Honsha Co Ltd | 抗癌剤耐性癌に対する治療剤 |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20040258754A1 (en) * | 2003-06-18 | 2004-12-23 | Valery Alakhov | Compositions for oral administration of camptothecin and its analogs |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| ES2629696T3 (es) | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| BRPI0415858A (pt) * | 2003-10-29 | 2007-01-09 | Sonus Pharma Inc | compostos de medicamentos terapêuticos modificados por tocoferol |
| WO2007106549A2 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Method for treating brain cancer |
| JP2010503706A (ja) * | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | リジン系ポリマーリンカー |
| US20090074074A1 (en) | 2007-06-29 | 2009-03-19 | The Hong Kong University Of Science And Technology | Multiple description encoder and decoder for transmitting multiple descriptions |
| KR101671537B1 (ko) * | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | 다분지형 중합체 알카노에이트 컨쥬게이트 |
| HUE047352T2 (hu) | 2008-09-23 | 2020-04-28 | Nektar Therapeutics | Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal) |
| CA2738807A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| CN101385860B (zh) * | 2008-10-31 | 2011-11-02 | 美国草药泉有限责任公司 | 喜树碱及其衍生物的非线性聚乙二醇前药 |
| US20120171201A1 (en) | 2009-07-22 | 2012-07-05 | Enzon Pharmaceuticals, Inc. | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
| CN102626518B (zh) * | 2012-05-09 | 2014-05-28 | 中国药科大学 | 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用 |
| CN104813167B (zh) | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| US9863949B2 (en) | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| US10758614B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016050210A1 (zh) | 2014-10-01 | 2016-04-07 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化聚乙二醇衍生物及其制备方法 |
| CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| US20200163956A1 (en) | 2016-09-06 | 2020-05-28 | Cerebral Therapeutics LLC | Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors |
| EP3613792B1 (en) | 2017-04-21 | 2021-02-24 | Bright Gene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
| JP7381083B2 (ja) | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
| WO2019090141A1 (en) | 2017-11-02 | 2019-05-09 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP7546552B2 (ja) * | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
-
2019
- 2019-09-17 JP JP2021514531A patent/JP7546552B2/ja active Active
- 2019-09-17 CA CA3112778A patent/CA3112778A1/en active Pending
- 2019-09-17 AU AU2019344783A patent/AU2019344783B2/en active Active
- 2019-09-17 KR KR1020217011264A patent/KR20210072002A/ko active Pending
- 2019-09-17 CN CN202510008384.XA patent/CN119950749A/zh active Pending
- 2019-09-17 MX MX2021003116A patent/MX2021003116A/es unknown
- 2019-09-17 EA EA202190799A patent/EA202190799A1/ru unknown
- 2019-09-17 WO PCT/US2019/051457 patent/WO2020061007A1/en not_active Ceased
- 2019-09-17 CN CN201980060783.3A patent/CN112996533B/zh active Active
- 2019-09-17 EP EP19863240.8A patent/EP3852793B1/en active Active
- 2019-09-17 US US16/969,790 patent/US11253603B2/en active Active
-
2022
- 2022-02-11 US US17/670,218 patent/US11642414B2/en active Active
-
2023
- 2023-04-27 US US18/140,289 patent/US12311028B2/en active Active
-
2025
- 2025-05-13 US US19/206,574 patent/US20250387496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230414766A1 (en) | 2023-12-28 |
| US11253603B2 (en) | 2022-02-22 |
| EP3852793B1 (en) | 2025-11-19 |
| NZ773863A (en) | 2024-10-25 |
| AU2019344783A1 (en) | 2021-04-08 |
| US11642414B2 (en) | 2023-05-09 |
| CN119950749A (zh) | 2025-05-09 |
| EP3852793A4 (en) | 2022-07-13 |
| KR20210072002A (ko) | 2021-06-16 |
| EP3852793A1 (en) | 2021-07-28 |
| JP2022501341A (ja) | 2022-01-06 |
| CN112996533B (zh) | 2025-01-10 |
| US20220160886A1 (en) | 2022-05-26 |
| JP7546552B2 (ja) | 2024-09-06 |
| CN112996533A (zh) | 2021-06-18 |
| US12311028B2 (en) | 2025-05-27 |
| WO2020061007A1 (en) | 2020-03-26 |
| EP3852793C0 (en) | 2025-11-19 |
| CA3112778A1 (en) | 2020-03-26 |
| US20250387496A1 (en) | 2025-12-25 |
| US20210000967A1 (en) | 2021-01-07 |
| EA202190799A1 (ru) | 2021-06-22 |
| AU2019344783B2 (en) | 2025-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37253A (es) | Compuestos conjugados de peg y carfilzomib | |
| MX2021003116A (es) | Profarmacos macromoleculares a base de polimero. | |
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| CY1126442T1 (el) | Αντισωματα anti-ntb-a και σχετικες συνθεσεις και μεθοδοι | |
| MX2024004433A (es) | Composiciones dirigidas. | |
| CY1125520T1 (el) | Μεθοδοι θεραπειας αμυλοειδωσης που διαμεσολαβειται με τρανσθυρετινη (ttr) | |
| CY1123441T1 (el) | Μορια με ειδικοτητα στα cd45 και cd79 | |
| CR20200082A (es) | Virus chikungunya inmunogénico | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CL2018003473A1 (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| UY36075A (es) | Derivados de tubulisina | |
| CY1125201T1 (el) | Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma) | |
| CL2020002637A1 (es) | Métodos de tratamiento de cáncer. | |
| MX358066B (es) | Óptimos loci de soya. | |
| ECSP19056271A (es) | Dendrímeros terapéuticos | |
| CY1124367T1 (el) | Ανθεκτικη στην υγρασια βιοαποικοδομησιμη συνθεση | |
| MX2024000877A (es) | Conjugados polimero-farmaco escindibles. | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
| BR112017017043A2 (pt) | composições e métodos para aprimorar aparência de pele | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| UY37108A (es) | Modificación de la composición de aceites de soja mediante el knockout dirigido de los genes fad3a/b/c | |
| CL2017000662A1 (es) | Inhibidores de la histona desmetilasa. | |
| MX390384B (es) | Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. |